Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?

Metabolism: Clinical and Experimental

Volumn 65, Issue 8, 2016, Pages 1087-1095

  Alkhouri, Naim ^a   Feldstein, Ariel E ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Biomarkers; Fibrosis; NASH

Indexed keywords

BIOLOGICAL MARKER;

APOPTOSIS; ARTICLE; DIAGNOSTIC IMAGING; ELASTOGRAPHY; HEPATITIS; HEPATOGRAPHY; HUMAN; LIVER CELL; LIVER EXAMINATION; LIVER FIBROSIS; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; BLOOD; DISEASE COURSE; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; UNITED STATES;

APOPTOSIS; BIOMARKERS; DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; UNITED STATES;

EID: 84960155207     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.01.013     Document Type: Article

References (75)

1. [1] Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D., Cohen, J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:6 (2004), 1387–1395 [PubMed PMID: 15565570].
2. [2] Schwimmer, J.B., Deutsch, R., Kahen, T., Lavine, J.E., Stanley, C., Behling, C., Prevalence of fatty liver in children and adolescents. Pediatrics 118:4 (2006), 1388–1393 [PubMed PMID: 17015527].
3. [3] Williams, C.D., Stengel, J., Asike, M.I., Torres, D.M., Shaw, J., Contreras, M., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140:1 (2011), 124–131 [PubMed PMID: 20858492].
4. [4] Boza, C., Riquelme, A., Ibanez, L., Duarte, I., Norero, E., Viviani, P., et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg 15:8 (2005), 1148–1153, 10.1381/0960892055002347 [PubMed PMID: 16197788].
5. [5] Vernon, G., Baranova, A., Younossi, Z.M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:3 (2011), 274–285, 10.1111/j.1365-2036.2011.04724.x PubMed PMID: 21623852.
6. [6] Matteoni, C.A., Younossi, Z.M., Gramlich, T., Boparai, N., Liu, Y.C., McCullough, A.J., Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:6 (1999), 1413–1419 [PubMed PMID: 10348825].
7. [7] Charlton, M., Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Curr Opin Organ Transplant 18:3 (2013), 251–258, 10.1097/MOT.0b013e3283615d30 [PubMed PMID: 23652610.
8. [8] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:6 (2012), 2005–2023 [PubMed PMID: 22488764].
9. [9] de Ledinghen, V., Vergniol, J., Capdepont, M., Chermak, F., Hiriart, J.B., Cassinotto, C., et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 60:5 (2014), 1026–1031, 10.1016/j.jhep.2013.12.018 [PubMed PMID: 24378529].
10. [10] Reeder, S.B., Cruite, I., Hamilton, G., Sirlin, C.B., Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging 34:4 (2011), 729–749, 10.1002/jmri.22580 [PubMed PMID: 21928307].
11. [11] Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385:9972 (2015), 956–965, 10.1016/S0140-6736(14)61933-4 [PubMed PMID: 25468160].
12. [12] Adams, L.A., Lymp, J.F., St Sauver, J., Sanderson, S.O., Lindor, K.D., Feldstein, A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129:1 (2005), 113–121 [PubMed PMID: 16012941].
13. [13] Ekstedt, M., Franzen, L.E., Mathiesen, U.L., Thorelius, L., Holmqvist, M., Bodemar, G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:4 (2006), 865–873 [PubMed PMID: 17006923].
14. [14] Musso, G., Gambino, R., Cassader, M., Pagano, G., Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43:8 (2011), 617–649 [PubMed PMID: 21039302].
15. [15] Alkhouri, N., Carter-Kent, C., Feldstein, A.E., Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol 5:2 (2011), 201–212 [PubMed PMID: 21476915].
16. [16] Feldstein, A.E., Wieckowska, A., Lopez, A.R., Liu, Y.C., Zein, N.N., McCullough, A.J., Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50:4 (2009), 1072–1078 [PubMed PMID: 19585618].
17. [17] Wieckowska, A., Zein, N.N., Yerian, L.M., Lopez, A.R., McCullough, A.J., Feldstein, A.E., In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44:1 (2006), 27–33 [PubMed PMID: 16799979].
18. [18] Feldstein, A.E., Alkhouri, N., De Vito, R., Alisi, A., Lopez, R., Nobili, V., Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol, 2013 [PubMed PMID: 23752877].
19. [19] Vuppalanchi, R., Jain, A.K., Deppe, R., Yates, K., Comerford, M., Masuoka, H.C., et al. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12:12 (2014), 2121–2130, 10.1016/j.cgh.2014.05.010 [PubMed PMID: 24846279]. [e1-2].
20. [20] Sanyal, A.J., Friedman, S.L., McCullough, A.J., Dimick-Santos, L., American Association for the Study of Liver D, United States F, et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases—U.S. Food and Drug Administration Joint Workshop. Hepatology 61:4 (2015), 1392–1405, 10.1002/hep.27678 [PubMed PMID: 25557690].
21. [21] Alkhouri, N., Alisi, A., Okwu, V., Matloob, A., Ferrari, F., Crudele, A., et al. Circulating soluble Fas and Fas ligand levels are elevated in children with nonalcoholic steatohepatitis. Dig Dis Sci 60:8 (2015), 2353–2359, 10.1007/s10620-015-3614-z [PubMed PMID: 25764498].
22. [22] Tamimi, T.I., Elgouhari, H.M., Alkhouri, N., Yerian, L.M., Berk, M.P., Lopez, R., et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 54:6 (2011), 1224–1229 [PubMed PMID: 21145805].
23. [23] Yilmaz, Y., Dolar, E., Ulukaya, E., Akgoz, S., Keskin, M., Kiyici, M., et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 13:6 (2007), 837–844 [PubMed PMID: 17352011].
24. [24] Younossi, Z.M., Page, S., Rafiq, N., Birerdinc, A., Stepanova, M., Hossain, N., et al. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 21:4 (2011), 431–439 [PubMed PMID: 20532833].
25. [25] Day, C.P., Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 16:5 (2002), 663–678 [PubMed PMID: 12406438].
26. [26] Oliveira, C.P., da Costa Gayotto, L.C., Tatai, C., Della Bina, B.I., Janiszewski, M., Lima, E.S., et al. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet. J Cell Mol Med 6:3 (2002), 399–406 [PubMed PMID: 12417056].
27. [27] Roskams, T., Yang, S.Q., Koteish, A., Durnez, A., DeVos, R., Huang, X., et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 163:4 (2003), 1301–1311 [PubMed PMID: 14507639].
28. [28] Videla, L.A., Rodrigo, R., Araya, J., Poniachik, J., Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med 37:9 (2004), 1499–1507 [PubMed PMID: 15454290].
29. [29] Gao, D., Wei, C., Chen, L., Huang, J., Yang, S., Diehl, A.M., Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. Am J Physiol Gastrointest Liver Physiol 287:5 (2004), G1070–G1077 [PubMed PMID: 15231485].
30. [30] Chalasani, N., Deeg, M.A., Crabb, D.W., Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99:8 (2004), 1497–1502 [PubMed PMID: 15307867].
31. [31] Feldstein, A.E., Lopez, R., Tamimi, T.A., Yerian, L., Chung, Y.M., Berk, M., et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res 51:10 (2010), 3046–3054 [PubMed PMID: 20631297].
32. [32] Alkhouri, N., Berk, M., Yerian, L., Lopez, R., Chung, Y.M., Zhang, R., et al. OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci 59:7 (2014), 1617–1624, 10.1007/s10620-014-3031-8 [PubMed PMID: 24464211; PubMed Central PMCID: PMC4279921].
33. [33] Abiru, S., Migita, K., Maeda, Y., Daikoku, M., Ito, M., Ohata, K., et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 26:1 (2006), 39–45 [PubMed PMID: 16420507].
34. [34] Wieckowska, A., Papouchado, B.G., Li, Z., Lopez, R., Zein, N.N., Feldstein, A.E., Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 103:6 (2008), 1372–1379 [PubMed PMID: 18510618].
35. [35] Alkhouri, N., Morris-Stiff, G., Campbell, C., Lopez, R., Tamimi, T.A., Yerian, L., et al. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int, 2011 [PubMed PMID: 22097893].
36. [36] Kowdley, K.V., Belt, P., Wilson, L.A., Yeh, M.M., Neuschwander-Tetri, B.A., Chalasani, N., et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 55:1 (2012), 77–85 [PubMed PMID: 21953442].
37. [37] Dixon, J.B., Bhathal, P.S., O'Brien, P.E., Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:1 (2001), 91–100 [PubMed PMID: 11438497].
38. [38] Zein, C.O., Edmison, J.M., Schluchter, M., Feldstein, A.E., Zein, N.N., McCullough, A., A NASH predictive index (NPI) for use in patients with nonalcoholic fatty liver disease [abstract]. Hepatology, 46(4), 2007, 747A.
39. [39] Poynard, T., Ratziu, V., Charlotte, F., Messous, D., Munteanu, M., Imbert-Bismut, F., et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol, 6, 2006, 34 [PubMed PMID: 17096854].
40. [40] Dongiovanni, P., Valenti, L., Genetics of nonalcoholic fatty liver disease. Metabolism 65 (2015), 1026–1037, 10.1016/j.metabol.2015.08.018 [PubMed PMID: 26409295].
41. [41] Hyysalo, J., Mannisto, V.T., Zhou, Y., Arola, J., Karja, V., Leivonen, M., et al. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol 60:4 (2014), 839–846, 10.1016/j.jhep.2013.12.009 [PubMed PMID: 24333862].
42. [42] Raposo, G., Stoorvogel, W., Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 200:4 (2013), 373–383, 10.1083/jcb.201211138 [PubMed PMID: 23420871; PubMed Central PMCID: PMC3575529].
43. [43] Kornek, M., Lynch, M., Mehta, S.H., Lai, M., Exley, M., Afdhal, N.H., et al. Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology 143:2 (2012), 448–458, 10.1053/j.gastro.2012.04.031 [PubMed PMID: 22537612; PubMed Central PMCID: PMC3404266].
44. [44] Povero, D., Eguchi, A., Li, H., Johnson, C.D., Papouchado, B.G., Wree, A., et al. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS One, 9(12), 2014, e113651, 10.1371/journal.pone.0113651 [PubMed PMID: 25470250; PubMed Central PMCID: PMC4254757].
45. [45] Mashir, A., Dweik, R.A., Exhaled breath analysis: the new interface between medicine and engineering. Adv Powder Technol 20:5 (2009), 420–425 [PubMed PMID: 20948990].
46. [46] Paschke, K.M., Mashir, A., Dweik, R.A., Clinical applications of breath testing. F1000 Med Rep, 2, 2010, 56 [PubMed PMID: 21173863].
47. [47] Paredi, P., Kharitonov, S.A., Barnes, P.J., Analysis of expired air for oxidation products. Am J Respir Crit Care Med 166:12 Pt 2 (2002), S31–S37, 10.1164/rccm.2206012 [PubMed PMID: 12471086].
48. [48] Verdam, F.J., Dallinga, J.W., Driessen, A., de Jonge, C., Moonen, E.J., van Berkel, J.B., et al. Non-alcoholic steatohepatitis: a non-invasive diagnosis by analysis of exhaled breath. J Hepatol 58:3 (2013), 543–548, 10.1016/j.jhep.2012.10.030 [PubMed PMID: 23142062].
49. [49] Angulo, P., Keach, J.C., Batts, K.P., Lindor, K.D., Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30:6 (1999), 1356–1362 [PubMed PMID: 10573511].
50. [50] Ratziu, V., Giral, P., Charlotte, F., Bruckert, E., Thibault, V., Theodorou, I., et al. Liver fibrosis in overweight patients. Gastroenterology 118:6 (2000), 1117–1123 [PubMed PMID: 10833486].
51. [51] Angulo, P., Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?. Hepatology 51:2 (2010), 373–375 [PubMed PMID: 20101746].
52. [52] Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwitthaya, P., et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 2015, 10.1053/j.gastro.2015.04.043 [PubMed PMID: 25935633].
53. [53] Ekstedt, M., Hagstrom, H., Nasr, P., Fredrikson, M., Stal, P., Kechagias, S., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61:5 (2015), 1547–1554, 10.1002/hep.27368 [PubMed PMID: 25125077].
54. [54] Harrison, S.A., Oliver, D., Arnold, H.L., Gogia, S., Neuschwander-Tetri, B.A., Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57:10 (2008), 1441–1447 [PubMed PMID: 18390575].
55. [55] Guha, I.N., Parkes, J., Roderick, P., Chattopadhyay, D., Cross, R., Harris, S., et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47:2 (2008), 455–460 [PubMed PMID: 18038452].
56. [56] McPherson, S., Stewart, S.F., Henderson, E., Burt, A.D., Day, C.P., Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 59:9 (2010), 1265–1269 [PubMed PMID: 20801772].
57. [57] Shah, A.G., Lydecker, A., Murray, K., Tetri, B.N., Contos, M.J., Sanyal, A.J., Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7:10 (2009), 1104–1112 [PubMed PMID: 19523535].
58. [58] Vallet-Pichard, A., Mallet, V., Nalpas, B., Verkarre, V., Nalpas, A., Dhalluin-Venier, V., et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 46:1 (2007), 32–36 [PubMed PMID: 17567829].
59. [59] Angulo, P., Hui, J.M., Marchesini, G., Bugianesi, E., George, J., Farrell, G.C., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:4 (2007), 846–854 [PubMed PMID: 17393509].
60. [60] Angulo, P., Bugianesi, E., Bjornsson, E.S., Charatcharoenwitthaya, P., Mills, P.R., Barrera, F., et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 145:4 (2013), 782–789 e4. [PubMed PMID: 23860502].
61. [61] Castera, L., Noninvasive evaluation of nonalcoholic fatty liver disease. Semin Liver Dis 35:3 (2015), 291–303, 10.1055/s-0035-1562948 [PubMed PMID: 26378645].
62. [62] Parkes, J., Roderick, P., Harris, S., Day, C., Mutimer, D., Collier, J., et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 59:9 (2010), 1245–1251 [PubMed PMID: 20675693].
63. [63] Ratziu, V., Massard, J., Charlotte, F., Messous, D., Imbert-Bismut, F., Bonyhay, L., et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol, 6, 2006, 6 [PubMed PMID: 16503961].
64. [64] Wilder, J., Patel, K., The clinical utility of FibroScan((R)) as a noninvasive diagnostic test for liver disease. Med Devices (Auckl) 7 (2014), 107–114, 10.2147/MDER.S46943 [PubMed PMID: 24833926; PubMed Central PMCID: PMC4014361].
65. [65] Bonder, A., Tapper, E.B., Afdhal, N.H., Contemporary assessment of hepatic fibrosis. Clin Liver Dis 19:1 (2015), 123–134, 10.1016/j.cld.2014.09.007 [PubMed PMID: 25454300].
66. [66] European Association for Study of L, Asociacion Latinoamericana para el Estudio del H, EASL-ALEH clinical practice guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63:1 (2015), 237–264, 10.1016/j.jhep.2015.04.006 [PubMed PMID: 25911335].
67. [67] Ebinuma, H., Saito, H., Komuta, M., Ojiro, K., Wakabayashi, K., Usui, S., et al. Evaluation of liver fibrosis by transient elastography using acoustic radiation force impulse: comparison with fibroscan((R)). J Gastroenterol 46:10 (2011), 1238–1248, 10.1007/s00535-011-0437-3 [PubMed PMID: 21779759].
68. [68] Friedrich-Rust, M., Romen, D., Vermehren, J., Kriener, S., Sadet, D., Herrmann, E., et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 81:3 (2012), e325–e331, 10.1016/j.ejrad.2011.10.029 [PubMed PMID: 22119555].
69. [69] Yoshioka, K., Hashimoto, S., Kawabe, N., Measurement of liver stiffness as a non-invasive method for diagnosis of non-alcoholic fatty liver disease. Hepatol Res 45:2 (2015), 142–151, 10.1111/hepr.12388 [PubMed PMID: 25040931].
70. [70] Kim, D., Kim, W.R., Talwalkar, J.A., Kim, H.J., Ehman, R.L., Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology 268:2 (2013), 411–419, 10.1148/radiol.13121193 [PubMed PMID: 23564711; PubMed Central PMCID: PMC3721049].
71. [71] Loomba, R., Wolfson, T., Ang, B., Booker, J., Behling, C., Peterson, M., et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology, 2014, 10.1002/hep.27362 [PubMed PMID: 25103310].
72. [72] Cui, J., Ang, B., Haufe, W., Hernandez, C., Verna, E.C., Sirlin, C.B., et al. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther 41:12 (2015), 1271–1280, 10.1111/apt.13196 [PubMed PMID: 25873207].
73. [73] Pavlides, M., Banerjee, R., Sellwood, J., Kelly, C.J., Robson, M.D., Booth, J.C., et al. Multi-parametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol, 2015, 10.1016/j.jhep.2015.10.009 [PubMed PMID: 26471505].
74. [74] Petta, S., Vanni, E., Bugianesi, E., Di Marco, V., Camma, C., Cabibi, D., et al. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 35:5 (2015), 1566–1573, 10.1111/liv.12584 [PubMed PMID: 24798049].
75. [75] Tapper, E.B., Sengupta, N., Hunink, M.G., Afdhal, N.H., Lai, M., Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography. Am J Gastroenterol 110:9 (2015), 1298–1304, 10.1038/ajg.2015.241 [PubMed PMID: 26303130].